Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

NCT04657315 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Adult Gliosarcoma
Neoplasms, Brain
Neoplasms, Germ Cell and Embryonal
Recurrent Glioblastoma

Interventions

DRUG: MSC11FCD

Sponsor

CHA University

Collaborators

[object Object]